Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LTR PharmaASX:LTP -6.19%4 EV-to-OCF is -8.96 as of Aug. 06, 2026. GuruFocus rates ASX:LTP with a GF Score™ of 4/100. Among 1,410 Biotechnology companies, LTR Pharma ranks better than 68.09% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, LTR Pharma's Enterprise Value is A$62.38 Mil.
LTR Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-6.96 Mil. Therefore, LTR Pharma's EV-to-OCF for today is -8.96.
The historical rank and industry rank for LTR Pharma's EV-to-OCF or its related term are showing as below:
ASX:LTP'
s EV-to-OCF Range Over the Past 10 Years
Min: -20.54 Med: -11.21 Max: -3.57
Current: -9.09
During the past 5 years, the highest EV-to-OCF of LTR Pharma was -3.57. The lowest was -20.54. And the median was -11.21.
ASX:LTP's EV-to-OCF is ranked better than 68.09% of 1410
companies
in the Biotechnology industry
Industry Median: -3.41
vs ASX:LTP: -9.09
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
LTR Pharma's share price for today is A$0.455.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. LTR Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.050.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
LTR Pharma EV-to-OCF Related Terms
LTR Pharma EV-to-OCF Historical Data
* Premium members only.
The historical data trend for LTR Pharma's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, LTR Pharma's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LTR Pharma EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, LTR Pharma's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where LTR Pharma's EV-to-OCF falls into.
LTR Pharma's current Enterprise Value is A$62.38 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. LTR Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-6.96 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTR Pharma (ASX:LTP) has a EV-to-OCF of -8.96 as of Aug. 06, 2026. According to the industry distribution chart, LTR Pharma ranks #450 out of 1410 companies in the Biotechnology industry, placing it in the top 31.9%.
Is LTR Pharma's EV-to-OCF too high?
LTR Pharma's current EV-to-OCF is -8.96. Based on the distribution chart, LTR Pharma ranks #450 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, LTR Pharma has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, LTR Pharma ranks #450 out of 1410 companies for EV-to-OCF. This puts LTR Pharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. LTR Pharma's current EV-to-OCF is -8.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current EV-to-OCF of -8.96. The current EV-to-OCF is -8.96. LTR Pharma's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current EV-to-OCF is -8.96 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
4GF Score
Get the complete analysis for ASX:LTP
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LTP has been successfully added to your 
